Vimarsana
Biggest News Aggregation in the World

Page 19 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

Accelerated Approval for Enhertu, HER2-Mutant Metastatic NSCLC - Vimarsana News

Accelerated Approval for Enhertu, HER2-Mutant Metastatic NSCLC

The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for previously treated adults with HER2-mutated unresectable or metastatic NSCLC.

Accelerated Approval for Enhertu, HER2-Mutant Metastatic NSCLC - Vimarsana News

Accelerated Approval for Enhertu, HER2-Mutant Metastatic NSCLC

The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for previously treated adults with HER2-mutated unresectable or metastatic NSCLC.

AstraZeneca & Daiichi drug wins another FDA approval, this time in lung cancer - Vimarsana News

AstraZeneca & Daiichi drug wins another FDA approval, this time in lung cancer

On the heels of receiving a landmark FDA approval in breast cancer, AstraZeneca and Daiichi Sankyo drug Enhertu won an additional approval in non-small cell lung cancer. The decision makes the drug the first targeted NSCLC therapy addressing the cancer protein HER2.

AstraZeneca PLC chemotherapy signed off for use in people with lung cancer - Vimarsana News

AstraZeneca PLC chemotherapy signed off for use in people with lung cancer

AstraZeneca PLC (LSE:AZN) said its drug Enhertu has been given the green light in the US to be given to patients with advanced and difficult-to-treat...

FDA Approves Enhertu (Trastuzumab Deruxtecan) for HER2 Lung Cancer - Vimarsana News

FDA Approves Enhertu (Trastuzumab Deruxtecan) for HER2 Lung Cancer

The agency has granted an accelerated approval for trastuzumab deruxtecan (Enhertu) to be used in patients with metastatic non–small cell lung cancer whose tumors have HER2 mutations.